Blog Archives

Venetoclax (Venclexta) for the treatment of patients with chronic lymphocytic leukemia (CLL)

April 12, 2016 – The American Food and Drug Administration (FDA) just approved Venetoclax (Venclexta) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with a least one prior therapy.

Read more ›

Tags: , , , , , , , , ,

Clinical phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL

Barr PM, Saylors GB, Spurgeon SE, Cheson BD, Greenwald DR, O’Brien SM, Liem AK, McIntyre RE, Joshi A, Abella-Dominicis E, Hawkins MJ, Reddy A, Di Paolo J, Lee H, He J, Hu J, Dreiling LK, Friedberg JW

Blood 2016 Mar;

PMID: 26968534

Abstract

Although agents targeting B-cell receptor signaling have provided practice-changing results in relapsed chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL),

Read more ›

Tags: , , , , , , ,

Ofatumumab (Arzerra) approved for recurrent or progressive chronic lymphocytic leukemia (CLL)

January 20, 2016 – The American Food and Drug Administration (FDA) just approved Ofatumumab (Arzerra)  Injection for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL). 

Read more ›

Tags: , , , , , , , , ,

The use of Ibrutinib [Imbruvica] expanded to the treatment of chronic lymphocytic leukaemia

July 28, 2014 – The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL.

Read more ›

Tags: , , ,

Idelalisib (Zydelig) for three types of blood cancers approved

July 23, 2014 – The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers.

Zydelig is being granted traditional approval to treat patients whose chronic lymphocytic leukemia (CLL) has returned (relapsed).

Read more ›

Tags: , , , , , , , , ,

thasso: conditions

thasso: newest tweets

thasso: recent comments

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Discovery of life in solid rock deep beneath sea may inspire new search for life on Mars April 2, 2020
    Newly discovered single-celled creatures living deep beneath the seafloor have provided clues about how to find life on Mars. These bacteria were discovered living in tiny cracks inside volcanic rocks after researchers perfected a new method cutting rocks into ultrathin slices to study under a microscope. Researchers estimate that the rock cracks are home to […]
  • Geneticists are bringing personal medicine closer to recently admixed individuals April 2, 2020
    A new study in Nature Communications proposes a method to extend polygenic scores, the estimate of genetic risk factors and a cornerstone of the personalized medicine revolution, to individuals with multiple ancestral origins. The study was led by Dr. Davide Marnetto from the Institute of Genomics of the University of Tartu, Estonia and coordinated by […]
  • Breast density, microcalcifications, and masses may be heritable traits April 2, 2020
    An analysis of a large Swedish cohort revealed that breast density, microcalcifications, and masses are heritable features, and that breast density and microcalcifications were positively associated with a genetic predisposition to breast cancer, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.
  • Impacts of cover crop planting dates on soil properties after 4 years April 2, 2020
    Low biomass production limits cover crop effects on soils.
  • A next-generation sensor network for tracking small animals April 2, 2020
    A newly developed wireless biologging network (WBN) enables high-resolution tracking of small animals, according to a study published April 2 in the open-access journal PLOS Biology by Simon Ripperger of the Leibniz Institute for Evolution and Biodiversity Science, and colleagues.
Top